Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells by Mise, Annarita Di et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2018-05-13 and may be subject to
change.
1Scientific REPORTS |  (2018) 8:5704  | DOI:10.1038/s41598-018-23732-5
www.nature.com/scientificreports
Activation of Calcium-Sensing 
Receptor increases intracellular 
calcium and decreases cAMP and 
mTOR in PKD1 deficient cells
Annarita Di Mise1, Grazia Tamma1,5, Marianna Ranieri1, Mariangela Centrone1,  
Lambertus van den Heuvel2, Djalila Mekahli3,4, Elena N. Levtchenko3,4 & Giovanna Valenti1,5,6
Clinical and fundamental research suggest that altered calcium and cAMP signaling might be the 
most proximal events in ADPKD pathogenesis. Cells from ADPKD cysts have a reduced resting 
cytosolic calcium [Ca2+]i and increased cAMP levels. CaSR plays an essential role in regulating calcium 
homeostasis. Its activation is associated with [Ca2+]i increase and cAMP decrease, making CaSR a 
possible therapeutic target. Human conditionally immortalized Proximal Tubular Epithelial cells 
(ciPTEC) with stable knockdown of PKD1 (ciPTEC-PC1KD) and ciPTEC generated from an ADPKD1 
patient (ciPTEC-PC1Pt) were used as experimental tools. CaSR functional expression was confirmed 
by studies showing that the calcimimetic NPS-R568 induced a significant increase in [Ca2+]i in ciPTEC-
PC1KD and ciPTEC-PC1Pt. Resting [Ca2+]i were significantly lower in ciPTEC-PC1KD with respect to 
ciPTECwt, confirming calcium dysregulation. As in native cyst cells, significantly higher cAMP levels 
and mTOR activity were found in ciPTEC-PC1KD compared to ciPTECwt. Of note, NPS-R568 treatment 
significantly reduced intracellular cAMP and mTOR activity in ciPTEC-PC1KD and ciPTEC-PC1Pt. To 
conclude, we demonstrated that selective CaSR activation in human ciPTEC carrying PKD1 mutation 
increases [Ca2+]i, reduces intracellular cAMP and mTOR activity, reversing the principal dysregulations 
considered the most proximal events in ADPKD pathogenesis, making CaSR a possible candidate as 
therapeutic target.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the fourth leading cause of end stage renal disease 
(ESRD) in adults, characterized by the progressive, bilateral growth and enlargement of fluid-filled cysts in kid-
neys that leads to a decline in renal function. It has a frequency of 1:400–1:10001 and 50% of adult PKD patients 
will require dialysis or kidney transplantation by their 6th decade. ADPKD is a dominant inherited disease caused 
by loss-of-function mutations in the PKD1 or PKD2 gene, encoding polycystin-1 (PC1) or polycystin-2 (PC2), 
respectively2. PKD1 is responsible for 85% of the cases in clinically-affected individuals (ADPKD1) and is associ-
ated with a more severe clinical course, while mutations in PKD2 are present in the remaining 15% of the patients 
(ADPKD2), who generally show a milder renal functional decline and a lower renal complication rate.
During the past few years, understanding of ADPKD pathogenesis has been considerably deepened, nev-
ertheless the function of the polycystins and the molecular mechanisms underlying cysts development are still 
poorly understood. Polycystins belong to a family of eight proteins containing transmembrane domains that 
form a heteromeric molecular complex in the plasma membrane and cilia3. PC1 is localized to the primary 
cilium and to the cell junctions where it probably functions as a receptor and/or adhesion molecule. PC2 is a 
calcium-permeable nonselective cation channel, expressed on the primary cilium, endoplasmic reticulum, and 
the plasma membrane. PC1 and PC2 interact to form the PC complex, which localizes to the primary cilia and 
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acts as a mechanosensor that controls calcium influx through the plasma membrane, induced by mechanical 
stimuli4,5. PC1 and PC2 are also known to regulate intracellular calcium release from the endoplasmic reticulum 
(ER) through their interaction with the inositol 1,4,5-trisphosphate receptor (IP3R)6–8. In conditionally immor-
talized, plasma membrane-permeabilized human proximal tubule epithelial cells, the simultaneous expression of 
both polycystins amplifies the IP3-induced calcium release, while PC1 alone or PC2 alone has no effect9. Despite 
the diversity of conclusions reached in the numerous studies analyzing the mechanisms involved in intracellular 
calcium regulation operated by PC1 and PC2, most of them are consistent with the hypothesis that polycystins by 
themselves and through their interaction with other calcium channels in the endoplasmic reticulum prevent the 
depletion of intracellular stores, maintaining the amplitude of physiological calcium oscillations10,11. The similar 
effect of both polycystins on the intracellular calcium homeostasis explains why loss-of-function mutations in the 
PKD1 or in the PKD2 genes both cause ADPKD.
Calcium signaling dysregulation is strictly correlated to another ADPKD hallmark represented by elevated 
cAMP levels. Numerous animal models of PKD show increased content of cAMP in the kidney12–16, an effect 
also observed in cholangiocytes17, in vascular smooth muscle cells18, and in choroid plexus19. Several hypoth-
eses have connected the increased levels of cAMP in PKD tissues to the dysregulation of intracellular calcium 
signaling, specifically correlating the reduced cytosolic calcium to both cAMP synthesis and hydrolysis. The dec-
rement in cytosolic calcium is supposed to cause the activation of the calcium-inhibitable adenylate cyclase 6 
(AC6), to directly inhibit calcium/calmodulin dependent phosphodiesterase 1 (PDE1) and to increase the levels 
of cyclic guanosine monophosphate, thus inhibiting indirectly the cyclic guanosine monophosphate-inhibitable 
PDE314,20. Increased cAMP levels are also attributable to the dysfunction occurred in the PC ciliary complex 
where the disruption of the PC2-mediated calcium entry, activates AC5/6 and inhibits phosphodiesterase 4C 
(PDE4C)21. Another study proposed the activation of the calcium-inhibitable AC6 due to the oligomeriza-
tion and translocation of STIM1 to the plasma membrane, caused by the ER calcium stores depletion22. cAMP 
increase causes protein Kinase A (PKA) activation, which leads to ERK-mediated phosphorylation of tuberin 
(the TSC2 gene product), inducing upregulation of the mammalian target of rapamycin, mTOR, implicated in 
the pro-proliferative pathway23–25. This process has also been linked to the abnormal transcriptional activation of 
aerobic glycolysis and intracellular ATP accumulation, allowing liver kinase B1 inhibition which, together with 
AMP-activated protein kinase (AMPK) inhibition, may further enhance mTOR signaling26,27.
The two crucial dysregulations in ADPKD, intracellular calcium and cAMP levels, are two pathways both 
regulated in the kidney by the activation of the extracellular calcium-sensing receptor (CaSR)28,29. CaSR is a 
G-protein-coupled receptor, originally cloned from the bovine parathyroid gland and successively identified in 
various organs30. Besides the parathyroid gland, the key CaSR-expressing organs are intestine, bone, and kid-
ney31,32. The CaSR senses changes in extracellular calcium concentrations and regulates parathyroid hormone 
(PTH) secretion and renal tubular calcium reabsorption to maintain serum calcium levels within the normal 
range. Increased serum calcium concentrations activate CaSR expressed in the parathyroid gland eliciting a 
Gq-protein cascade that activates the phospholipase C (PLC) pathway and prevents exocytosis of PTH33. In the 
proximal tubule, CaSR is expressed on the apical membrane and its activation evoked by an increment in luminal 
calcium, decreases PTH-induced intracellular cAMP accumulation by inhibiting adenylate cyclase 629,34.
In a recent work, we have shown that conditionally immortalized human proximal tubular epithelial cells 
(ciPTEC), isolated from urine of a healthy subject, express a functional CaSR sensitive to its physiological ago-
nist, calcium, and its positive allosteric modulator, NPS-R568, resulting in a release of calcium from intracellular 
stores35. Moreover, receptor activation was found to cause a significant decrease in intracellular cAMP levels35.
In the present study, we investigated the expression of CaSR in ciPTEC with stable knockdown of PKD1 as 
well as in ciPTEC isolated from urine of a PKD1 patient. Of note, we show that CaSR activation increased cyto-
solic calcium, and reduced intracellular cAMP levels and mTOR activity thus improving the principal dysregula-
tions of signaling molecules considered the most proximal events in the pathogenesis of ADPKD, making CaSR 
a possible therapeutic target candidate.
Results
Expression and functional characterization of CaSR in ciPTECwt and ciPTEC-PC1KD. The 
endogenous CaSR expression in ciPTEC stably knocked down for polycystin-19 (ciPTEC-PC1KD) and in the 
wild type clone (ciPTECwt) was evaluated by Western blotting. Both cell type expressed the monomeric form at 
130 kDa, the glycosylated monomeric one at 160 kDa, and the dimeric receptor at 250 kDa (Fig. 1A). Moreover, 
no difference in CaSR expression levels was observed in the two cell lines (data not shown). Immunofluorescence 
CaSR localization in monolayers of polarized ciPTEC revealed an apical plasma membrane expression of the 
receptor in both cell lines as it occurs in native renal proximal tubule epithelial cells (Fig. 1B).
In a previous study, we have provided the first evidence that ciPTEC isolated from urine of a healthy volunteer 
endogenously express a functional CaSR35. Here, we show that both ciPTECwt and ciPTEC-PC1KD also express 
a functional receptor. Cells were loaded with 6 μM Fura-2 AM and stimulated with the positive allosteric CaSR 
modulator NPS-R568 (10 μM) known to increase the sensitivity of the receptor for calcium36. CaSR stimula-
tion caused a significant increase in Ca2+i in both ciPTECwt and ciPTEC-PC1KD as showed in Fig. 2A and B, 
reporting a representative time course of fluorescence responses. Nevertheless, Ca2+i increase in ciPTECwt was 
significantly higher with respect to the one observed in ciPTEC-PC1KD. Statistical analysis of the fluorescence 
responses revealed that cytosolic calcium levels were 90.68 ± 2.47% (vs. ATP 100%, n = 40) in ciPTECwt and 
24.32 ± 2.59% (vs. ATP 100%, n = 47) in ciPTEC-PC1KD, P<0.0001 (Fig. 2C).
Intracellular and ER calcium content in ciPTECwt and ciPTEC-PC1KD. Polycystin dysfunctions 
have been proven to cause a reduction in steady state calcium levels37 which contributes to cyst formation38,39. 
It has been shown that cultured epithelial cells derived from human ADPKD cysts have a basal intracellular 
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calcium content approximately 20 nM lower than normal human kidney (NHK) cells38. Therefore, we first meas-
ured the cytosolic calcium levels at rest in our cell models. Calcium calibration experiments revealed a signif-
icant lower [Ca2+]i in ciPTEC-PC1KD compared to ciPTECwt (ciPTEC-PC1KD = 93.44 ± 4.13 nM, n = 107; 
ciPTECwt = 113.4 ± 3.7 nM, n = 95; P = 0.0004), confirming calcium dysregulation in ADPKD cells and in ani-
mal models (Fig. 3A).
Since it is known that PC complex disruption has implications in abnormal ER calcium depletion11,40, FRET 
experiments were performed to measure calcium levels in the ER. ciPTEC-PC1KD had significant lower ER 
Figure 1. Endogenous CaSR expression and localization in ciPTECwt and ciPTEC-PC1KD. (A) 
Immunodetection of CaSR in homogenates of ciPTECwt and ciPTEC-PC1KD, after 11 days of maturation 
at 37 °C. Specific anti-CaSR antibodies revealed both CaSR forms at 130 and 250 kDa, corresponding to the 
monomeric and mature receptor. The figure shows a representative blot. (B) Immunofluorescence localization 
of CaSR in polarized ciPTEC, showing its predominant apical plasma membrane localization.
Figure 2. Effects of CaSR positive allosteric modulator, NPS-R568, on (Ca2+)i levels. ciPTECwt (A) and 
ciPTEC-PC1KD (B) were grown for 11 days at 37 °C and stimulated with NPS-R568 10 μM and ATP 100 μM. 
Fluorescence ratio 340/380 nm was recorded. Each trace is representative of 4 different experiments with similar 
results. (C) Fluorescence ratio 340/380 nm was recorded and responses to NPS-R568 were calculated as the 
percentage of changes in fluorescence (Delta Ratio Fura-2%), normalized to the fluorescence ratio observed in 
the presence of the ATP stimulus (100%). Histogram shows a significant lower intracellular calcium increase 
in ciPTEC-PC1KD compared to ciPTECwt. Data were analyzed with One-way ANOVA followed by Newman-
Keuls multiple comparisons test and are expressed as means ± SEM (**P < 0.01 vs. ATP; ****P < 0.0001 vs. 
ATP or ciPTECwt).
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calcium levels compared with ciPTECwt (Fig. 3B), consistent with the lower increase in intracellular calcium after 
CaSR stimulation showed in Fig. 2C (ciPTEC-PC1KD = 90.46 ± 2.09%, n = 140, vs. ciPTECwt = 100%, n = 152; 
P = 0.0008).
CaSR activation decreases cAMP levels in ciPTEC-PC1KD. As in native cells from cysts41, signif-
icantly higher cAMP levels were found under basal conditions in ciPTEC-PC1KD with respect to ciPTECwt 
(ciPTEC-PC1KD = 104.6 ± 0.81%, n = 96, vs. ciPTECwt = 100%, n = 114; P<0.0001) (Fig. 4). Interestingly, 
treatment of cells with the CaSR positive allosteric modulator NPS-R568 (10 μM for 30 min) induced a signif-
icant decrease in ciPTEC-PC1KD intracellular cAMP content (ciPTEC-PC1KD + NPS-R568 = 99.76 ± 0.68%, 
n = 115), approaching the levels observed in ciPTECwt at basal conditions. This result represents the first evi-
dence that cells knocked down for PC1 expressing an endogenous functional CaSR, respond to the calcimimetic 
NPS-R568 with a significant reduction in cAMP intracellular levels, thus attenuating one of the pivotal dysregu-
lations characterizing ADPKD.
mTOR dysregulation is improved by CaSR activation in ciPTEC-PC1KD. mTOR activity was inves-
tigated by the evaluation of the phosphorylated forms of its downstream effector, the S6 ribosomal protein, and its 
upstream effector, AMP-activated protein kinase (AMPK). Specifically, S6 is used as a marker of mTORC1 path-
way activation42. mTOR signaling activates p70S6 kinase which in turn phosphorylates Ser235, Ser236, Ser240 
and Ser244 of S643. Anti-pS6 (Ser235/236) antibodies were used for pS6 immunodetection (Fig. 5). pS6 expres-
sion at rest was significantly higher in ciPTEC-PC1KD compared with ciPTECwt (ciPTECwt = 1 ± 0.06, n = 10; 
ciPTEC-PC1KD = 2.88 ± 0.6, n = 8; P<0.001). Importantly, CaSR activation by NPS-R568 (10 μM for 30 min), 
reduced S6 protein levels in ciPTEC-PC1KD to those observed in ciPTECwt at basal conditions (ciPTEC-PC1
KD + NPS-R568 = 1.07 ± 0.3, n = 10). CaSR stimulation did not affect pS6 levels in ciPTECwt with respect to 
untreated cells.
Conversely, mTOR is known to be inhibited by AMPK44, and AMPK activity is decreased in PC1 knocked 
down cells compared with control. We evaluated AMPK in ciPTEC by Western blotting experiments 
(Fig. 6) examining its phosphorylation at Thr172 in the α subunit (pAMPK). The phosphorylated levels of 
AMPK were significantly lower in ciPTEC-PC1KD compared to ciPTECwt (ciPTECwt = 1 ± 0.05, n = 15; 
ciPTEC-PC1KD = 0.58 ± 0.09, n = 15; P<0.0001). After treatment with NPS-R568 (10 μM for 30 min), pAMPK 
levels in ciPTEC-PC1KD were reversed to levels comparable to wt cells (ciPTEC-PC1KD + NPS-R568 = 1.32 ± 0
.2, n = 15). No changes were observed in pAMPK expression in ciPTECwt after NPS-R568 treatment with respect 
to untreated cells.
AMPK regulates mTOR also through the direct phosphorylation of the tumor suppressor TSC244, resulting 
in mTOR inhibition. We therefore evaluated the serine/threonine kinase Akt, an upstream negative regulator of 
TSC2, whose activation mediates cell growth, proliferation, and survival. In ciPTEC-PC1KD cells, the levels of 
phosphorylated Akt (pAkt, Ser-473) were significantly reduced with respect to wt (ciPTECwt CTR = 1 ± 0.05, 
Figure 3. Calcium content in ciPTECwt and ciPTEC-PC1KD. (A) Intracellular calcium concentrations 
measurement obtained by calcium calibration experiments. Cells were loaded with 6 μM Fura-2 AM for 15 min 
at 37 °C. Free cytosolic Ca2+ was calculated accordingly to Grynkiewicz formula. Histogram shows a significant 
lower intracellular calcium concentration in ciPTEC-PC1KD compared to ciPTECwt. Data were analyzed by 
unpaired t-test and are expressed as means ± SEM (***P = 0.0004). (B) Evaluation of Ca2+ER with ER-targeted 
Cameleon (D1ER) FRET probe. Binding of calcium to calmodulin sequence results in an intramolecular 
rearrangement of the probe leading to an increase in netFRET signal. Histogram (means ± SEM, ***P = 0.0008) 
compares changes in normalized FRET (netFRET) ratio between ciPTECwt and ciPTEC-PC1KD, analyzed by 
unpaired t-test.
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ciPTEC-PC1KD CTR = 0.57 ± 0.11, n = 8; P<0.01) (Fig. 7). Interestingly, CaSR stimulation with NPS-R568, 
by increasing cytosolic calcium concentration, elicited an increase in pAkt in ciPTEC-PC1KD with respect to 
ciPTECwt, restoring the basal content (ciPTEC-PC1KD + NPS-R568 = 1.16 ± 0.13, n = 8). Since increased Akt 
activity inhibits cAMP-dependent B-Raf/ERK, ERK/pERK were next evaluated. pERK 1/2 levels were found 
increased in ciPTEC-PC1KD compared to ciPTECwt (ciPTECwt = 1 ± 0.02, ciPTEC-PC1KD = 1.89 ± 0.34, 
n = 7; P < 0.05) (Fig. 8). Interestingly, CaSR activation decreased pERK 1/2 expression in ciPTEC-PC1KD to the 
levels observed in wt cells (ciPTEC-PC1KD + NPS-R568 = 0.82 ± 0.3, n = 7).
Figure 4. Evaluation of cAMP levels in ciPTECwt and ciPTEC-PC1KD by FRET analysis. At resting, ciPTEC-
PC1KD presented a significant higher cAMP content with respect to ciPTECwt. Interestingly, CaSR stimulation 
elicited by NPS-R568 10 μM induced a significant decrease in cAMP content in ciPTEC-PC1KD, restoring 
levels comparable to ciPTECwt at basal conditions. All data were analyzed by One-way ANOVA followed by 
Newman-Keuls multiple comparisons test and are expressed as means ± SEM (*P < 0.01 ciPTECwt CTR vs. 
ciPTECwt + NPS-R568; ***P < 0.0001 ciPTEC-PC1KD CTR vs. ciPTEC-PC1KD + NPS-R568; #P < 0.0001 
ciPTEC-PC1KD CTR vs. ciPTECwt CTR).
Figure 5. NPS-R568 effect on mTOR expression and activity in ciPTECwt and ciPTEC-PC1KD, analyzed 
by pS235/236-S6 (pS6) evaluation. (A) Equal amount of proteins from cells (30 μg) were immunoblotted for 
total S6 and pS6. The figure shows representative blots. (B) Signals were semiquantified by densitometry. 
Statistical analysis performed with One-way ANOVA followed by Newman-Keuls multiple comparisons test 
(means ± SEM, *P < 0.001 ciPTEC-PC1KD CTR vs. ciPTECwt CTR or ciPTECwt + NPS-R568 or ciPTEC-
PC1KD + NPS-R568) revealed that pS6 expression, higher in ciPTEC-PC1KD compared to ciPTECwt, was 
restored at the same levels of ciPTECwt at rest by the treatment with NPS-R568.
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CaSR activation reverses PKD1 dysregulations in ciPTEC isolated from an ADPKD1 patient. 
The effect of CaSR activation in ciPTEC-PC1Pt was next evaluated. The absence of immunoreactive PC1 band 
in the ADPKD patient (10.032) was previously reported45. CaSR expression was confirmed by Western blot-
ting experiments, showing the presence of both the forms of the receptor, the monomeric and mature protein 
(Fig. 9A), and by confocal analysis in monolayers of polarized ciPTEC-PC1Pt proving the apical localization of 
CaSR (Fig. 9B).
The functional expression of the receptor present in ciPTEC-PC1Pt was next evaluated by single-cell epiflu-
orescence imaging. Cells were loaded with 6 μM Fura-2 AM and treated with 10 μM NPS-R568 (Fig. 10A). As 
ciPTEC-PC1KD, ciPTEC-PC1Pt responded to CaSR activation with a significant increase in cytosolic calcium 
(29.51 ± 3.93% vs. ATP 100%, n = 38, P < 0.0001) (Fig. 10B). Interestingly, the calcium levels observed were com-
parable with those reported in ciPTEC-PC1KD, suggesting a similar dysregulation in calcium homeostasis in cells 
isolated from ADPKD1 patient urine as well.
Of note, as observed in ciPTEC-PC1KD, CaSR stimulation with NPS-R568 caused a significant reduction of 
cAMP levels also in ciPTEC-PC1Pt (ciPTEC-PC1Pt + NPS-R568 = 78.01 ± 4.04%, n = 120, vs. ciPTEC-PC1Pt 
CTR = 100%, n = 140; P = 0.0006; Fig. 11).
Figure 6. AMPK phosphorylation levels under NPS-R568 effect in ciPTECwt and ciPTEC-PC1KD. (A) Equal 
amount of proteins (30 μg) were immunoblotted with antibodies specific for total AMPK or for pT172-AMPK 
(pAMPK). The figure shows representative blots. (B) Densitometric analysis and statistical studies performed 
with One-way ANOVA followed by Newman-Keuls multiple comparisons test (means ± SEM) revealed that 
pAMPK levels in ciPTEC-PC1KD were significantly lower with respect to ciPTECwt. CaSR stimulation with 
NPS-R568 restored levels comparable to ciPTECwt at rest (*P < 0.0001 ciPTEC-PC1KD CTR vs. ciPTECwt 
CTR; **P < 0.001 ciPTEC-PC1KD + NPS-R568 vs. ciPTEC-PC1KD CTR).
Figure 7. NPS-R568 effect on Akt expression in ciPTECwt and ciPTEC-PC1KD. (A) Equal amount of proteins 
from cells (30 μg) were immunoblotted for total Akt and Akt phosphorylated at Ser473 (pAkt). The figure 
shows representative blots. (B) Densitometric and statistical analysis (means ± SEM, *P < 0.01 ciPTEC-PC1KD 
CTR vs. ciPTECwt CTR; #P < 0.01 ciPTEC-PC1KD + NPS-R568 vs. ciPTEC-PC1KD CTR) demonstrated 
significantly lower pAkt levels in ciPTEC-PC1KD compared to ciPTECwt. CaSR stimulation with NPS-R568 
increased pAkt to levels detected in ciPTECwt at rest. One-way ANOVA followed by Newman-Keuls multiple 
comparisons test was used to analyze data.
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The expression and activity of mTOR and AMPK were also evaluated in ciPTEC-PC1Pt. CaSR activation 
with NPS-R568 caused a significant decrease in pS6 levels compared to unstimulated cells which reflects a 
lower mTOR activity in response to CaSR activation in this cell line (ciPTEC-PC1Pt + NPS-R568 = 0.52 ± 0.0
8, n = 10, vs. ciPTEC-PC1Pt CTR = 1 ± 0.09, n = 10; P = 0.0004; Fig. 12). Conversely, CaSR stimulation resulted 
in an increased AMPK activity as demonstrated by the significantly higher levels of the phosphorylated form in 
NPS-R568 treated cells (ciPTEC-PC1Pt + NPS-R568 = 1.51 ± 0.22, n = 8, vs. ciPTEC-PC1Pt CTR = 1 ± 0.07, 
n = 11; P = 0.02; Fig. 13).
Discussion
The major results obtained in this work can be summarized as follows: a. ciPTEC with stable knockdown of 
PKD1 or isolated from the urine of an ADPKD1 patient endogenously express functional CaSR; b. both cell lines 
showed the same dysregulations in intracellular calcium, cAMP and mTOR pathways reported in animal models 
of ADPKD112,14,20,46–50 and human polycystic kidneys38,51; c. these dysregulations were reversed by activation of 
CaSR with the allosteric modulator NPS-R568. These results indicate that CaSR may represent a therapeutic tar-
get in Autosomal Dominant Polycystic Kidney Disease 1.
The first evidence that ciPTEC isolated from urine of a healthy volunteer endogenously express a functional 
CaSR was recently provided by our group35. We showed that CaSR activation causes a decrease in cytosolic cAMP 
Figure 8. Effect of CaSR stimulation on ERK 1/2 expression in ciPTECwt and ciPTEC-PC1KD. (A) Equal 
amount of proteins from cells (30 μg) were immunoblotted for total ERK 1/2 and ERK 1/2 phosphorylated 
at Thr185/Tyr187 (pERK 1/2). The figure shows representative blots. (B) Signals were semiquantified by 
densitometry. Statistical analysis (means ± SEM, *P < 0.05 ciPTEC-PC1KD CTR vs. ciPTECwt CTR or 
ciPTEC-PC1KD + NPS-R568 vs. ciPTEC-PC1KD CTR) revealed significantly higher pERK 1/2 expression in 
ciPTEC-PC1KD compared to ciPTECwt. CaSR stimulation with NPS-R568 restored the same levels of pERK 
1/2 to levels detected in ciPTECwt at rest. One-way ANOVA followed by Newman-Keuls multiple comparisons 
test was used to analyze data.
Figure 9. Endogenous CaSR expression and localization in ciPTEC-PC1Pt. (A) After 11 days of maturation 
at 37 °C, cells were homogenized and CaSR immunodetection was performed. Specific anti-CaSR antibodies 
revealed the expression of both CaSR forms at 130 and 250 kDa, corresponding to the monomeric and mature 
receptor. The figure shows a representative blot. (B) Immunofluorescence staining of CaSR, showing its apical 
plasma membrane expression in a confluent monolayer of ciPTEC-PC1Pt.
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content and an increase in intracellular calcium attributable to CaSR coupling to Gq, resulting in PLC activation 
and IP3-dependent release of calcium from intracellular stores35. In the aim of exploring, at cellular level, the 
potentiality of CaSR as therapeutic target in the treatment of ADPKD, we considered, as valuable model system, 
ciPTEC obtained by immortalizing cells exfoliated from urine sediments of an ADPKD1 patient and ciPTEC 
obtained from healthy subject, knocked down for PKD1.
The complexity of the renal cyst formation still makes ADPKD a poorly understood disease, nevertheless it 
is known to involve cell clonal proliferation, increased apoptosis, abnormal epithelial cell phenotype, extracel-
lular matrix alterations and inflammation52,53. Recent evidence suggests that for cystogenesis to occur, there is 
Figure 10. Functional characterization of endogenous CaSR in ciPTEC-PC1Pt. (A) Cells were grown for 
11 days at 37 °C and stimulated with NPS-R568 10 μM and ATP 100 μM. Fluorescence ratio 340/380 nm was 
recorded. Each trace is representative of 3–4 different experiments with similar results. (B) Histogram shows 
that NPS-R568 stimulation in ciPTEC-PC1Pt elicited an intracellular calcium increase comparable to the one 
obtained in ciPTEC-PC1KD. Fluorescence ratio 340/380 nm was recorded and responses to NPS-R568 were 
calculated as the percentage of changes in fluorescence (Delta Ratio Fura-2%), normalized to the fluorescence 
ratio observed in the presence of the ATP stimulus (100%). Data were analyzed with One-way ANOVA followed 
by Newman-Keuls multiple comparisons test and are expressed as means ± SEM (****P < 0.0001 vs. ATP).
Figure 11. Effect of CaSR activation on cAMP content in ciPTEC-PC1Pt. FRET experiments revealed that 
CaSR stimulation with NPS-R568 10 μM significantly reduced cAMP levels in ciPTEC-PC1Pt with respect to 
untreated cells. Data are expressed as means ± SEM (***P = 0.0006).
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no requirement of a complete loss of PC1 or PC2 function, but their functionality must be reduced to a certain 
threshold level, which marks the correspondence between PC1 dosage and rate of disease severity4. In the renal 
collecting duct, mutations in PKD1 or PKD2 are associated with a decrease in intracellular calcium and increase 
in cAMP with consequent activation of PKA exposing collecting duct principal cells to the constant tonic effect of 
vasopressin, activating downstream signaling pathways responsible for impaired tubulogenesis, cell proliferation, 
increased fluid secretion, and interstitial inflammation54.
The pivotal role of cAMP in the pathogenesis of ADPKD represents a key point for treatment strategies ration-
ale to lower its levels in cystic tissues. Clinical trials of vasopressin receptor 2 (V2R) antagonists have shown 
encouraging results. In fact, several studies demonstrated that V2 receptor antagonists (mozavaptan and/or 
tolvaptan) attenuate the progression of PKD in cpk mice and pcy mouse models of nephronophthisis (NPHP), 
ARPKD (PCK rats), and PKD2 (Pkd2WS25/− mice)14,47,48,55. The V2R antagonist tolvaptan, by inhibiting the bind-
ing of vasopressin to the receptor, promotes aquaresis and lowers cAMP synthesis, slowing progression of renal 
cysts also in humans as shown in randomized placebo-controlled clinical trials56–59.
However, since the V2R is not present in the proximal tubule, tolvaptan would have no effect on cysts orig-
inating from this segment and a therapy directed to the proximal tubular cysts would probably improve the 
Figure 12. Effect of CaSR stimulation on mTOR expression and activity in ciPTEC-PC1Pt, evaluated by 
pS235/236-S6 (pS6) levels analysis. (A) Equal amount of proteins from cells (30 μg) were immunoblotted for 
total S6 and pS6. The figure shows representative blots. (B) Densitometric and statistical analysis performed 
with unpaired t-test (means ± SEM, ***P = 0.0004) revealed that pS6 expression was significantly decreased by 
the treatment with NPS-R568 compared to untreated cells.
Figure 13. NPS-R568 stimulation effect on AMPK phosphorylation levels in ciPTEC-PC1Pt. (A) Equal 
amount of proteins (30 μg) were immunoblotted with antibodies specific for total AMPK or for pT172-AMPK 
(pAMPK). The figure shows representative blots. (B) Signals were semiquantified by densitometry. Statistical 
analysis (means ± SEM, *P = 0.02) demonstrated that CaSR activation elicited a significant increase in pAMPK 
levels with respect to untreated cells. Data were analyzed by unpaired t-test.
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suboptimal efficiency of tolvaptan therapy. Interestingly, a recent study60 showed that treatment of pcy mice (a 
NPHP orthologous animal model), with the calcimimetic NPS-R568, a positive allosteric CaSR modulator, inhib-
ited progression of cysts growth and renal fibrosis. NPS-R568 was less effective in later-stage NPHP but did 
significantly reduce kidney weight60. In an interesting work, Gattone and coworkers61 showed that NPS-R568, 
administrated to male Cy/+ rats from 20 to 38 weeks of age, an age when CKD is well established, reduced 
the development of renal cysts and ameliorated the kidney cystic disease. In contrast, another study evaluating 
the effect of CaSR activation with NPS-R568 in animal models orthologous to human ADPKD and/or ARPKD 
(Autosomal Recessive Polycystic Kidney Disease), reported no detectable effect on cystogenesis but possible ben-
eficial effect on interstitial fibrosis15,16,62,63. A possible explanation for the lack of calcimimetic effect is that the 
administration of NPS-R568 resulted in hypocalcemia and therefore it is likely that the effects of NPS-R568 on 
intracellular calcium and cAMP are negated by the reduction in extracellular calcium.
In the present study, we show the cellular effect of CaSR activation with NPS-R568 on the most proximal 
events in ADPKD pathogenesis, calcium and cAMP, in ciPTEC of human proximal tubule origin stably knocked 
down for PKD1 or isolated from the urine of an ADPKD1 patient. Both the cell lines expressed the monomeric 
and the mature glycosylated forms of CaSR that localized at the apical plasma membrane as in native proximal 
tubule cells. At basal conditions, ciPTEC-PC1KD showed lower cytosolic calcium concentrations with respect to 
ciPTECwt, reporting one of the two major dysregulations observed in ADPKD1 animal models. Of note, func-
tional experiments showed that CaSR activation, elicited by NPS-R568 stimulation, caused an increase in cyto-
solic calcium both in ciPTEC-PC1KD and ciPTEC-PC1Pt both having calcium values significantly lower than 
ciPTECwt. In a previous work, we already showed that CaSR expressed in ciPTEC couples to Gq and its activation 
results in PLC activation and IP3-dependent release in intracellular calcium, likely from endoplasmic reticulum35. 
Several studies highlighted the primary role of the PC complex interaction with other calcium channels expressed 
in the ER in preventing the depletion of intracellular stores, especially of the ER itself10,11,40. Here, we demon-
strated a lower calcium content, at steady state, in the ER of ciPTEC-PC1KD compared to ciPTECwt, sustaining 
the hypothesis that the lower intracellular calcium increase observed in ciPTEC-PC1KD and ciPTEC-PC1Pt 
was due to a lower calcium content in the ER, attributable to the presence of a loss-of-function mutation in PC1, 
which leads to PC complex disruption and dysfunction. Moreover, as mentioned before, intracellular calcium 
decrement in ADPKD has been correlated to cAMP increase also observed in ciPTEC-PC1KD. Interestingly, 
NPS-R568 treatment elicited a significant decrease in cAMP content in ciPTEC-PC1KD and in ciPTEC-PC1Pt, 
restoring levels comparable to ciPTECwt at basal conditions. We show here that CaSR activation had a positive 
effect also on mTOR activity, which is upregulated in cystic kidney epithelial cells showing altered cell prolifera-
tion. In normal kidney, PC1 and TSC1/TSC2 interaction inhibits mTOR, preventing an abnormal activation of 
the proliferative pathway. By contrast in ADPKD, PC1 dysfunction precludes the TSC1/TSC2 complex formation 
promoting mTOR activation, through a mechanism involving the cAMP-dependent B-Raf/ERK pathway64,65. 
Specifically, in human primary ADPKD cyst epithelial cells it has been shown that increase in intracellular cAMP 
activates PKA leading to B-Raf and hence MEK and ERK activation25. In addition, it has been reported that dis-
ruption of intracellular calcium mobilization operated by calcium channel blockers was associated with decreased 
activity of Akt, a negative regulator of B-Raf, resulting in activation of the B-Raf/ERK pathway66.
In line with these results, lower levels of pAkt and increased pERK have been found in ciPTEC-PC1KD. Of 
note, NPS-R568 treatment induced an increase in pAkt and a reduction in pERK levels. It has to be pointed 
out that pAkt is an upstream positive regulator of mTOR through TSC2 inhibition expected to increase mTOR 
signaling. However, the overall reduction in mTOR signaling observed in ciPTEC-PC1KD cells in response to 
NPS-R568 can be due to the observed activation of AMPK known to reduce mTOR signaling through TSC2 
phosphorylation44,67 which might overcome the pAkt effect.
AMPK is activated by Ca2+/calmodulin-dependent protein kinase-β (CaMKKβ) in response to an increase 
in cytosolic calcium concentration68. We report here that AMPK is downregulated in ciPTEC-PC1KD and 
NPS-R568 stimulation caused a significant increase in pAMPK either in ciPTEC-PC1KD and ciPTEC-PC1Pt.
Therefore, CaSR showed a regulatory effect on multiple defective pathways either in ciPTEC-PC1KD 
and ciPTEC-PC1Pt, potentiating the relevance that CaSR stimulation might have in improving ADPKD 
dysregulations.
To summarize, we have shown that selective CaSR activation in human ciPTEC carrying PKD1 mutation 
increases intracellular calcium, reduces cAMP and mTOR activity thus reversing the principal dysregulations 
of the molecules considered the most proximal events in the pathogenesis of ADPKD. Although ciPTEC are of 
proximal origin, it has to be underlined that CaSR is expressed in all nephron segments with an apical localization 
in the proximal tubule and in the collecting duct, and a basolateral distribution in the thick ascending limb where 
it displays the highest expression34. Therefore, in vivo, calcimimetics are expected to act in the entire nephron. 
Moreover, being CaSR also express in liver69, calcimimetics may also act on liver cysts also found in ADPKD 
patients. Investigating in vitro effects of the treatment with calcimimetics in human renal cells deriving from 
ADPKD patient has potentially important implications at several levels. Firstly, it can contribute to elucidate 
in much greater detail the pathophysiology of ADPKD. Secondly, it can have a direct impact on a novel way 
for ADPKD treatment as CaSR is expressed in all nephron segments where it counteracts the hormones acting 
through cAMP/PKA pathways making CaSR a promising candidate for therapeutic intervention in ADPKD.
Methods
Materials. All chemicals were purchased from Sigma (Sigma-Aldrich, Milan, Italy). Fura-2 AM was obtained 
from Molecular Probes (Life Technologies, Monza, Italy). NPS-R568 was kindly gifted by Amgen (Amgen Dompé 
S.p.a., Milan, Italy). Media for cell culture were from Lonza (Lonza s.r.l., Milan, Italy).
www.nature.com/scientificreports/
1 1Scientific REPORTS |  (2018) 8:5704  | DOI:10.1038/s41598-018-23732-5
Antibodies. Monoclonal CaSR antibody recognizing amino-acid 15–29 at the extracellular N-terminus was 
from Sigma-Aldrich, Milan, Italy. Rabbit anti-Phospho-S6RP (Ser235/236), anti-Tot S6RP, anti-Phospho-AMPK 
(Thr172 of its α subunit) and anti-Tot AMPK antibodies were purchased from Cell Signaling Technology 
(Beverly, Massachusetts, USA). Mouse anti-ERK 1/2 and rabbit anti-Phospho-ERK 1/2 (Thr185/Tyr187) were 
from Merck Millipore (Darmstadt, Germany). Secondary goat anti-rabbit, goat anti-mouse and goat anti-mouse 
IgG biotin antibodies were purchased from Sigma-Aldrich, Milan, Italy. Streptavidin-488 conjugate was from 
Alexa Fluor (Molecular Probes, Eugene, Oregon, USA).
Generation of ciPTEC knocked down for polycystin-1 or from ADPKD1 patient. ciPTEC were 
generated as described by Wilmer and colleagues70. Primary cells were cultured by collecting mid-stream urine 
within 5 h after collection. Urine sediment was resuspended in DMEM Ham’s F12 medium supplemented with 
10% fetal bovine serum (FBS), 100 IU/ml penicillin, 100 mg/ml streptomycin, ITS (5 μg/ml insulin, 5 μg/ml trans-
ferrin and 5 ng/ml selenium), 36 ng/ml hydrocortisone, 10 ng/ml epidermal growth factor (EGF) and 40 pg/ml 
triiodothyronine. The suspension was placed at 37 °C in a 5% CO2 incubator.
Primary cells were immortalized as previously described70. Briefly, cells were infected with SV40T and hTERT 
vectors, containing respectively geneticin (G418) and hygromycin resistance71,72. Subconfluent cell layers were 
transferred to 33 °C and selected by using G418 (400 μg/ml) and hygromycin B (25 μg/ml) for 10 days. Stable 
knocked down ciPTEC for polycystin-1 (ciPTEC-PC1KD) were obtained transducing a cloned ciPTEC line 
(ciPTECwt) of a healthy individual (34.8) by adding lentiviral vectors encoding miR-shRNA directed against 
polycystin-1, cloned in tandem (pCHMWS Bsd 2xmiRNA PKD1), to the culture medium9. Transduced cells were 
selected using 10 g/ml blasticidin. Alternatively, ciPTEC derived from an ADPKD1 patient (10.032) with known 
germline PKD1 mutation (ciPTEC-PC1Pt) were isolated as described45,70. Experiments were performed prior 
cellular maturation for 11 days at 37 °C. The reduced expression of PC1 was showed by Mekahli and coworkers 
which biochemically characterized these cell lines9,45.
Immunofluorescence Microscopy. Immunofluorescence localization of CaSR in polarized ciPTEC was 
performed as previously described35,73. Cells were incubated with antibodies diluted in block solution containing 
2% (w/v) bovine serum albumin (BSA) and 0.1% (v/v) tween-20 in HBSS against the calcium-sensing receptor 
(CaSR, 1:800 dilution) at 4 °C overnight. Following treatment with secondary rabbit-anti-mouse-biotin antibod-
ies followed by Streptavidin-488, samples were mounted on glass slides with Mowiol. Images were obtained with 
a confocal microscope Leica TCS SP2 (Leica Microsystems, Heerbrugg, Switzerland).
Cell Preparations. ciPTEC were seeded onto 100-mm dishes and grown at 37 °C for 11 days, then were lysed 
in Cell Fractionation Buffer (20 mM NaCl, 130 mM KCl, 1 mM MgCl2, 10 mM Hepes, pH 7.5) in the presence of 
proteases (1 mM PMSF, 2 mg/ml leupeptin and 2 mg/ml pepstatin A) and phosphatases (10 mM NaF and 1 mM 
sodium orthovanadate) inhibitors. Cellular debris was removed by centrifugation at 12,000 × g for 20 min at 4 °C. 
The supernatants were collected and used for immunoblotting studies.
Gel Electrophoresis and Immunoblotting. ciPTEC lysates were separated on 10% bis-tris acrylamide 
gels under reducing conditions. Protein bands were electrophoretically transferred onto Immobilon-P mem-
branes (Millipore Corporate Headquarters, Billerica, USA) for Western blot analysis, blocked in TBS-Tween-20 
containing 5% BSA and incubated with primary antibodies O/N. Anti-CaSR was used at 1:800 dilution, 
anti-Phospho-S6RP and anti-Tot S6RP were used at 1:1000 dilution, anti-Phospho-AMPK and anti-Tot AMPK 
at 1:500 dilution. Immunoreactive bands were detected with secondary antibodies conjugated to horseradish 
peroxidase (HRP) obtained from SantaCruz Biotechnologies (Tebu-Bio, Milan, Italy). Membranes were devel-
oped using Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, USA) with Chemidoc System 
(Bio-Rad Laboratories, Milan, Italy). Representative figures are shown. Densitometry analysis was performed 
with Scion Image. Data were summarized in histograms with GraphPad Prism (Graphpad Software Inc. La Jolla, 
CA, USA).
Video-Imaging Experiments. ciPTEC were grown on 25-mm glass coverslips at 37 °C for 11 days, then 
were loaded with 6 μM Fura-2 AM for 15 min at 37 °C in DMEM. Ringer’s Solution was used to perfuse cells 
during the experiment containing 120 mM NaCl, 4 mM KCl, 15 mM NaHCO3, 1 mM MgCl2, 15 mM Hepes, 
0.5 mM NaH2PO4, 10 mM Glucose, 1 mM CaCl2, 0.5 mM Na2HPO4, 0.4 mM MgSO4, pH 7.4 (modified by9,36). 
Measurements were performed using an inverted microscope (Nikon Eclipse TE2000-S microscope) equipped 
for single cell fluorescence measurements and imaging analysis. The sample was illuminated through a 40 × oil 
immersion objective (NA = 1.30). The Fura-2 AM loaded sample was excited at 340 and 380 nm. Emitted fluo-
rescence was passed through a dichroic mirror, filtered at 510 nm (Omega Optical, Brattleboro, VT, USA) and 
captured by a cooled CCD camera (Cool SNAP HQ, Photometrics). The ratio of fluorescence intensities at 340 
and 380 nm was plotted using Metafluor software (Molecular Devices, MDS Analytical Technologies, Toronto, 
Canada).
For the experiments at steady state, intracellular calcium level was calibrated and then calculated as described 
by Grynkiewicz74. Briefly, intracellular calcium concentration (Ca2+)i was determined from the emission fluores-
cence ratio of the two excitation wavelengths accordingly to the formula (Ca2+)i = Kd · Q(R − Rmin)/(Rmax − R), 
where Kd (224 nM) indicates the dissociation constant of Fura-2 AM for (Ca2+)i and Q indicates the ratio of the 
fluorescence intensities (F) at the minimum and the maximum calcium concentration at 380 nm. Each sample 
was calibrated by the addition of 5 μM ionomycin in the presence of 1 mM EGTA (Rmin) followed by 5 μM iono-
mycin in 5 mM CaCl2 (Rmax).
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Fluorescence Resonance Energy Transfer (FRET) Measurements. To evaluate intracellular cAMP 
levels and endoplasmic reticulum (ER) calcium content, fluorescence resonance energy transfer (FRET) exper-
iments were performed as described35. Briefly, ciPTEC were seeded onto 20-mm glass coverslips at 37 °C for 
11 days. For cytosolic cAMP evaluation, cells were transiently transfected with a plasmid encoding the H96 
probe containing cAMP binding sequence of Epac1 between CFP and cp173Venus-Venus75. For ER calcium levels 
measurements, cells were transiently transfected with a plasmid encoding the D1ER Cameleon76. Experiments 
were performed 48 hours post-transfection. Cells were left under basal condition or, for intracellular cAMP evalu-
ation, also stimulated with NPS-R568 (10 μM for 30 min at 37 °C) in Ringer’s solution described above, containing 
2 mM CaCl2.
FRET measurements were carried out using MetaMorph software (Molecular Devices, MDS Analytical 
Technologies, Toronto, Canada). CFP and YFP were excited at 436 and 500 nm, respectively; fluorescence emit-
ted was measured at 480/40 nm for CFP and 535/30 nm for YFP and FRET. Corrected normalized FRET values 
were determined as already described77,78. Each image was corrected for CFP cross-talk and YFP cross-excitation. 
Therefore, netFRET = [IFRETbg − ICFPbg K1 − IYFPbg · (K2 − αK1)]/(1 − δK1) where IFRETbg, ICFPbg, and 
IYFPbg are the background-corrected pixel gray values measured in the FRET, CFP and YFP windows, respec-
tively; K1, K2, α and δ are calculated to evaluate the crosstalk between donor and acceptor. The integrated fluores-
cence density values of the images from each cell were analyzed using MetaMorph and Microsoft Excel software.
Statistical analysis. One-way ANOVA followed by Newman-Keuls multiple comparisons test or t-test were 
used for the statistical analysis. All values are expressed as means ± SEM. A difference of P < 0.05 was considered 
statistically significant.
Data availability statement. All data generated or analysed during this study are included in this pub-
lished article.
Ethical approval and informed consent. The current study is in accordance with the institutional ethical 
guidelines for obtaining human cell lines for research and was approved by the corresponding ethical commit-
tee at University Hospitals Leuven. An informed consent was obtained from all participants and/or their legal 
guardian/s.
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